Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001

Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001

Provides up to six months treatment with CuATSM for subjects who have successffulyl completed study CMD-2019-001. [This allows subjects randomized to placebo on study CMD-2019-001 to receive up to six months treatment with CuATSM and provides an up to an additional six months treatment with CuATSM for subjects randomized to CuATSM on study CMD-2019-001]

Inclusion Criteria:

• signed informed consent prior to initiation of any study-specific procedures and treatment
• documented completion of protocol-specified assessments following completion of 24 weeks treatment on study CMD-2019-002
• Investigator considers patient has been tolerating treatment on study CMD-2019-001 and may benefit from continued treatment with CuATSM

Exclusion Criteria:

• not dependent on mechanical ventilation